60 DEGREES PHARMACEUTICALS, INC. Stock-Based Compensation
60 DEGREES PHARMACEUTICALS, INC. (SXTP) reported Stock-Based Compensation of $212.60 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2025-03-27
- 60 DEGREES PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2023-12-31 was $0.00.
- 60 DEGREES PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2023-09-30 was $271.07K.
- 60 DEGREES PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2023-06-30 was $65.00K.
- 60 DEGREES PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for the quarter ending 2023-03-31 was $212.60K.
- 60 DEGREES PHARMACEUTICALS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $212.60K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $271.07K derived: sum of 2 quarters · filed 2025-03-27 | $336.07K derived: sum of 3 quarters · filed 2025-03-27 | $212.60K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $271.07K 10-Q · filed 2023-11-20 | $336.07K derived: sum of 2 quarters · filed 2024-08-14 | $212.60K 10-Q · filed 2024-11-14 | $670.87K 10-Q · filed 2023-11-20 | |
| 2023-06-30 | $65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $277.61K 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | $212.60K 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 |